BioCentury
ARTICLE | Clinical News

Zevalin ibritumomab tiuxetan regulatory update

January 31, 2011 8:00 AM UTC

Spectrum submitted a post-approval supplement to FDA for Zevalin ibritumomab tiuxetan to remove the requirement for Zevalin indium-111 pre-treatment imaging evaluation. Spectrum said removing the bios...